Free Trial
NASDAQ:MDWD

MediWound (MDWD) Stock Price, News & Analysis

MediWound logo
$18.27 -1.00 (-5.19%)
As of 03:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About MediWound Stock (NASDAQ:MDWD)

Key Stats

Today's Range
$18.50
$19.68
50-Day Range
$15.98
$20.33
52-Week Range
$12.78
$24.00
Volume
53,666 shs
Average Volume
89,950 shs
Market Capitalization
$197.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.33
Consensus Rating
Buy

Company Overview

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Remove Ads

MediWound Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

MDWD MarketRank™: 

MediWound scored higher than 28% of companies evaluated by MarketBeat, and ranked 830th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MediWound has only been the subject of 2 research reports in the past 90 days.

  • Read more about MediWound's stock forecast and price target.
  • Earnings Growth

    Earnings for MediWound are expected to grow in the coming year, from ($2.66) to ($2.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MediWound is -6.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MediWound is -6.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MediWound has a P/B Ratio of 5.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about MediWound's valuation and earnings.
  • Percentage of Shares Shorted

    12.91% of the float of MediWound has been sold short.
  • Short Interest Ratio / Days to Cover

    MediWound has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MediWound has recently increased by 15.48%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    MediWound does not currently pay a dividend.

  • Dividend Growth

    MediWound does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.91% of the float of MediWound has been sold short.
  • Short Interest Ratio / Days to Cover

    MediWound has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MediWound has recently increased by 15.48%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    MediWound has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for MediWound this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, MediWound insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.20% of the stock of MediWound is held by insiders.

  • Percentage Held by Institutions

    46.83% of the stock of MediWound is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MediWound's insider trading history.
Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

MDWD Stock News Headlines

Lying in hospital… staring at the light
"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.
MediWound Q4 2024 Earnings Preview
Mediwound (MDWD) Receives a New Rating from Craig-Hallum
Craig-Hallum starts MediWound with Buy on EscharEx potential
See More Headlines

MDWD Stock Analysis - Frequently Asked Questions

MediWound's stock was trading at $17.80 at the start of the year. Since then, MDWD stock has increased by 2.6% and is now trading at $18.27.
View the best growth stocks for 2025 here
.

MediWound Ltd. (NASDAQ:MDWD) released its earnings results on Wednesday, March, 19th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.25. MediWound had a negative trailing twelve-month return on equity of 82.17% and a negative net margin of 142.29%.

MediWound's stock reverse split on the morning of Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Top institutional investors of MediWound include Yelin Lapidot Holdings Management Ltd. (7.89%), Essex Investment Management Co. LLC (1.38%), Northern Trust Corp (1.34%) and Sargent Investment Group LLC (1.12%).

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MediWound investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Palo Alto Networks (PANW).

Company Calendar

Today
3/19/2025
Last Earnings
3/19/2025
Next Earnings (Estimated)
3/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medicinals & botanicals
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MDWD
Employees
80
Year Founded
2001

Price Target and Rating

Average Stock Price Target
$31.33
High Stock Price Target
$39.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+71.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,720,000.00
Net Margins
-142.29%
Pretax Margin
-141.46%

Debt

Sales & Book Value

Annual Sales
$19.72 million
Price / Cash Flow
N/A
Book Value
$3.43 per share
Price / Book
5.33

Miscellaneous

Free Float
9,794,000
Market Cap
$197.06 million
Optionable
Optionable
Beta
0.82

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:MDWD) was last updated on 3/19/2025 by MarketBeat.com Staff
From Our Partners